Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
33.96
+0.26 (+0.77%)
Official Closing Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
29
30
31
32
33
34
35
36
Next >
White House Commits $3B To Boost COVID-19 Vaccine Supply Chain: Report
September 03, 2021
The U.S. will invest $3 billion in the COVID-19 vaccine supply chain within the coming weeks, White House coronavirus response coordinator Jeff Zients said Thursday....
Via
Benzinga
Exposures
COVID-19
Can Vaccine Help In Long Term COVID-19 Symptoms? UK Study Gives Encouraging Answer
September 02, 2021
According to findings from a new U.K. study, along with reducing the risk of severe disease and hospitalization, COVID-19 vaccines can also lower the odds of having long-term...
Via
Benzinga
Exposures
COVID-19
The Rising Delta Variant
September 01, 2021
China is not only cracking down on kiddie playtime. It also is absorbing bankruptcy claims from real estate developer Evergrande.
Via
Talk Markets
Topics
Bankruptcy
Exposures
Financial
Legal
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
August 31, 2021
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The...
Via
Benzinga
Exposures
COVID-19
Friday: Quick Update
August 27, 2021
Britain - which I actually will be escaping soon - had a better market day than many foreign markets.
Via
Talk Markets
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
August 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...
Via
Benzinga
3 Things About Pfizer That Smart Investors Know
August 31, 2021
They're all about the future.
Via
The Motley Fool
This Biotech Company Could Offer Nearly Unlimited Optionality
August 28, 2021
Backed by its growing genetic database, 23andMe could take its business in a number of lucrative directions.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
EU Says Without EMA Approval COVID-19 Boosters May Face Higher Legal Risks: Reuters
August 26, 2021
European Union countries that decide to use COVID-19 vaccine booster shots may face increased legal risks, the European Commission said. Related Content: Pfizer, BioNTech...
Via
Benzinga
Exposures
COVID-19
5 Best Dividend Stocks To Buy Now
August 26, 2021
There's no better time than now to invest in dividend stocks. And some of the best dividend stocks that beat the S&P 500's average yield of 2% can be found in the healthcare sector.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
August 25, 2021
The second-quarter earnings season was a strong one for the drug/biotech sector.
Via
Talk Markets
Theravance Stock Crashes; Can Longer Testing Salvage Its J&J-Partnered Drug?
August 24, 2021
Theravance said late Monday its ulcerative colitis treatment failed in midstage testing, and the biotech stock plummeted early Tuesday.
Via
Investor's Business Daily
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
August 24, 2021
Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the...
Via
Benzinga
Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia
August 23, 2021
The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab,...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
August 22, 2021
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues,...
Via
Benzinga
Exposures
Product Safety
2 SPACs That Look Like Bargains After Post-Earnings Drops
August 22, 2021
Many recent SPAC IPOs have been hammered, and these two could be worth a closer look.
Via
The Motley Fool
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
August 20, 2021
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by...
Via
Benzinga
Exposures
Product Safety
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
August 19, 2021
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.
Via
The Motley Fool
Exposures
COVID-19
GlaxoSmithKline PLC Looks To Continue To Trade Above Its Annual-High Share Price Today
August 18, 2021
GlaxoSmithKline PLC (NYSE: GSK) traded at a new 52-week high today of $42.68. This new high was reached on below-average trading volume as 1.4 million shares traded hands, while...
Via
Benzinga
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
August 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
August 18, 2021
The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with...
Via
Benzinga
Exposures
Product Safety
Stocks That Hit 52-Week Highs On Tuesday
August 17, 2021
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) was the largest company by market cap to set a new 52-week...
Via
Benzinga
4 High-Yield Dividend Stocks to Boost Your Dividend Income
August 17, 2021
Dividends paid by GlaxoSmithKline plc, Vector Group Ltd, Star Group, L.P., and Ennis, Inc translate to high yields at their current price levels.
Via
Talk Markets
Large Cap Biopharma Stocks provide Growth and Value
August 16, 2021
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Sunday Update - UK Disarray, Brazilian Kisses
August 15, 2021
News from the UK, China and Brazil, with the latest from Cosan.
Via
Talk Markets
Friday the Thirteenth
August 13, 2021
The stock week in points eastward was mixed. The USA markets face a bear correction.
Via
Talk Markets
82 Firms Going Ex-Dividend Next Week, Including Target, Walgreens Boots Alliance and GlaxoSmithKline
August 13, 2021
There are several well-known large-cap stocks going ex-dividend next week.
Via
Talk Markets
Do mRNA COVID-19 Vaccines Cause Skin Or Kidney Disorders? EMA Investigates Possible Links
August 12, 2021
The European Medicines Agency is investing a possible link between mRNA vaccines and erythema multiforme or two kidney disorders by a few recipients of the shots....
Via
Benzinga
Exposures
COVID-19
The Real World
August 11, 2021
The rise of the delta has caused markets to drop back after the rises earlier although inflation still remains within a point or two of forecasts at 5.3-5.4% annualized.
Via
Talk Markets
< Previous
1
2
...
29
30
31
32
33
34
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.